Dark Matter Bio
A venture-built thesis at the edge of bioscience, data, and longevity.
Four converging forces creating unprecedented opportunity
Why Now
A demographic shift creating a multi-trillion dollar opportunity
The UN describes global aging as "a defining trend of our time" and a "major success story"
Validated genomic tools, mechanism-based geroscience, and AI-native R&D have transformed longevity into an investable category
Evolved from basic gene editing to base editing, prime editing, and epigenome editing—enabling precise interventions in age-related pathways.
Drugs that selectively clear senescent "zombie" cells, implicated in chronic inflammation and age-related diseases.
Applied to multi-omics datasets and biomarker streams to identify aging signatures and enable biological-age-driven interventions.
A multi-trillion dollar market underpinned by demographic certainty
Join Us
Demographic inevitability meets scientific readiness
Breakthroughs in genomics, epigenetics, proteomics, and other biosciences are enabling new ways to understand and treat disease.
Newly discovered biomarkers, combined with real-time data collection, give us continuous, measurable signals about biological age, risk, and response.
Consumers and institutions are demanding personalized, data-driven, future-forward health innovations, not one-size-fits-all care.
Repeat founders from software and infrastructure now want to apply their company-building craft to breakthroughs in health and longevity.
What sets us apart in the longevity investment landscape
Trusted networks at the intersection of Silicon Valley, bioscience research, inventors, and company builders.
Investing partners with a track record several standard deviations above venture in general, including biotech and health.
Deep domain experience paired with the entrepreneurial energy of a modern venture firm.
Geekery, alignment, and wide, deep relationships across the ecosystem give Dark Matter the right to win the most interesting opportunities.
Investing at the edge of what's knowable.
fund@darkmatter.bio
Why Dark Matter
Scientific depth, exclusive access, and tight focus on defensible longevity technologies
in longevity biology
via Stanford & Cedars-Sinai partnerships
Ben Greenfield, Bryan Johnson, Peter Attia
Focus on defensible platforms
Our differentiation is not theoretical—it's embedded in who we are
Partner With Us
A Team That Speaks Both Lab and Late-Stage Capital
Scientific depth meets investment discipline
Returns
Two proven paths to liquidity for longevity investments
IPOs and strategic M&A remain durable outcomes in biotech
Biotech IPOs remain a core liquidity event, especially for companies with differentiated clinical data in age-related disease.
Large pharma companies facing patent cliffs are increasingly acquiring longevity-adjacent assets to sustain growth.
2024–2035
Pharma–Senolytics Acquisition Model
Returns
Two proven paths. Multiple ways to win.
Liquidity is built into the category: public markets and strategic M&A.
Fund Strategy
A systematic strategy for diversification, reserves, and concentration in winners
Institutional terms, aligned incentives
Mix of entry pricing + validation + reserves
Concentrated where exits and talent density are strongest
Lead ownership at entry, reserves for true outliers
Reserve rules concentrate capital behind the highest conviction
Diversification with a written concentration framework
Institutional Grade
Category-defining companies through critical inflection points